Skip to main content

Advertisement

Table 1 Patient characteristics

From: Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative 18F-FDG PET/CT analysis

Characteristic All patients (n = 64)
Gender
 Male 40 (62.5%)
 Female 24 (37.5%)
Age (years) at baseline PET/CT 59 (45–69) (range 25–80)
World Health Organization performance
 0 45 (70.3%)
 1 7 (10.9%)
 ≥ 2 7 (11.0%)
 Missing 5 (7.8%)
Histology primary melanoma
 Cutaneous 47 (73.4%)
 Mucosal 4 (6.3%)
 Primary melanoma unknown/missing 13 (20.3%)
M-stage at baseline PET/CT
 M1a 1 (1.6%)
 M1b 2 (3.1%)
 M1c 61 (95.3%)
No. of different metastatic locationsa
 1 3 (4.7%)
 2 6 (9.4%)
 > 2 55 (85.9%)
Organ involvement
 (Sub)cutaneous 39 (60.9%)
 Lymph nodes 54 (84.4%)
 Lungs 40 (62.5%)
 Muscular 25 (39.1%)
 Skeletal 39 (60.9%)
 Liver 24 (37.5%)
 Abdomenb 30 (46.9%)
 Otherc 14 (21.9%)
Brain metastasesd
 Yes 22 (34.4%)
  18F-FDG-avide 11 (17.2%)
  Not 18F-FDG-avid 11 (17.2%)
 No 35 (54.7%)
 Missing 7 (10.9%)
BRAF mutation status
BRAFV600 mutation 31 (48.4%)
 No BRAFV600 mutation 33 (51.6%)
RAS mutation status
RAS mutationf 15 (23.4%)
 No RAS mutation 49 (76.6%)
Baseline serum LDH (U/l) 246 (192–327) (range 92–11,371)
 Normal 35 (54.7%)
 Elevatedg 28 (43.7%)
  > 1–2× ULN 23 (35.9%)
  > 2× ULN 5 (7.8%)
 Missing 1 (1.6%)
Interval between baseline PET/CT and LDH measurement (days) 0 (− 7 to + 3) (range − 39 to + 11)
  1. Data are displayed as n (%) or median (interquartile range)
  2. LDH lactate dehydrogenase, ULN upper limit of normal
  3. aIncluding brain metastases
  4. bNumber of patients with lesions in the abdominal cavity/peritoneum (n = 27; 42.2% of all patients), adrenal gland (n = 12; 18.8%), bowel (n = 6; 9.4%), spleen (n = 3; 4.7%), kidney (n = 2; 3.1%), gallbladder (n = 1; 1.6%), stomach (n = 1; 1.6%), rectum (n = 1; 1.6%) and/or pancreas (n = 1; 1.6%)
  5. cNumber of patients with lesions in the vaginal or nasal mucosa (n = 4; 6.3%), myelum (n = 1; 1.6%), shoulder joint (n = 2; 3.1%), breast (n = 2; 3.1%), pericardium (n = 3; 4.7%), heart (n = 2; 3.1%) and/or abdominal or thoracic wall of undetermined tissue of origin (n = 2; 3.1%)
  6. dBased on MRI brain (n = 53) or, when missing, contrast enhanced CT (n = 4)
  7. eI.e. distinguishable from normal brain tissue
  8. fNRAS (n = 14) and KRAS (n = 1)
  9. gI.e. > 250 U/l